On Monday, Tango Therapeutics Inc (NASDAQ: TNGX) opened higher 18.63% from the last session, before settling in for the closing price of $7.14. Price fluctuations for TNGX have ranged from $1.03 to $8.80 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 7.47% over the past five years. Company’s average yearly earnings per share was noted 7.66% at the time writing. With a float of $64.33 million, this company’s outstanding shares have now reached $110.87 million.
Let’s look at the performance matrix of the company that is accounted for 155 employees.
Tango Therapeutics Inc (TNGX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tango Therapeutics Inc is 42.18%, while institutional ownership is 73.25%. The most recent insider transaction that took place on Sep 25 ’25, was worth 4,008,500. In this transaction 10% Owner of this company sold 500,000 shares at a rate of $8.02, taking the stock ownership to the 13,863,975 shares. Before that another transaction happened on Sep 25 ’25, when Company’s 10% Owner proposed sale 500,000 for $7.80, making the entire transaction worth $3,900,000.
Tango Therapeutics Inc (TNGX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.27 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.37) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.69% during the next five years compared to 7.47% growth over the previous five years of trading.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
Check out the current performance indicators for Tango Therapeutics Inc (TNGX). In the past quarter, the stock posted a quick ratio of 4.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 38.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.33, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -1.40 in one year’s time.
